What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2).

September 18, 2025JAMA OncologyOpen Access

Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial reports 39.4% overall response rate in advanced penile cancer patients, suggesting chemotherapy-immune therapy synergy.

Overall response rate was 39.4% in patients treated with pembrolizumab and platinum-based chemotherapy.
Median progression-free survival was reported at 5.4 months and overall survival at 9.6 months.
The study followed up 33 eligible patients for two years across 11 centers in Brazil.
Treatment-related adverse event rates were 91.9% for any grade and 51.4% for grades 3 to 4, indicating manageable safety.

Maluf et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark